Revenue reached $257.7 million in 2026Q1, though gross margins have faced pressure, declining from 44.8% in 2025Q3 to 41.8% in the most recent period.
| Sales/Revenue | 1B | 980.6M |
| Revenue Growth % | - | - |
| Cost of Goods Sold | 574.33M | 572.79M |
| COGS % of Revenue | - | 58.41% |
| Gross Profit | 430.61M | 407.81M |
| Gross Margin % | 42.85% | 41.59% |
| Gross Profit Growth % | - | - |
| Operating Expenses | 333.02M | 291.14M |
| OpEx % of Revenue | - | 29.69% |
| Selling, General & Admin | 204.47M | 195.66M |
| SG&A % of Revenue | - | 19.95% |
| Research & Development | 95.5M | 95.48M |
| R&D % of Revenue | - | 9.74% |
| Other Operating Expenses | 2M | 0 |
| Operating Income | 97.59M | 116.66M |
| Operating Margin % | 9.71% | 11.9% |
| Operating Income Growth % | - | - |
| EBITDA | 160.12M | 178.6M |
| EBITDA Margin % | 15.93% | 18.21% |
| EBITDA Growth % | - | - |
| D&A (Non-Cash Add-back) | 62.53M | 61.93M |
| EBIT | 110.09M | 116.66M |
| Net Interest Income | -17.67M | -21.47M |
| Interest Income | 0 | 0 |
| Interest Expense | 17.67M | 21.47M |
| Other Income/Expense | -28.02M | -47.02M |
| Pretax Income | 69.58M | 69.64M |
| Pretax Margin % | 6.92% | 7.1% |
| Income Tax | 15.86M | 15.81M |
| Effective Tax Rate % | 22.79% | 22.71% |
| Net Income | 53.72M | 53.83M |
| Net Margin % | 5.35% | 5.49% |
| Net Income Growth % | - | - |
| Net Income (Continuing) | 53.72M | 53.83M |
| Discontinued Operations | 0 | 0 |
| Minority Interest | 0 | 0 |
| EPS (Diluted) | 1.31 | 1.47 |
| EPS Growth % | - | - |
| EPS (Basic) | - | 1.47 |
| Diluted Shares Outstanding | 41.16M | 36.7M |
| Basic Shares Outstanding | 40.42M | 36.59M |
| Dividend Payout Ratio | - | - |
Integration and M&A execution
According to the provided quarterly income statement data, Novanta Inc. demonstrated a steady revenue trajectory, reaching $257.7 million in 2026Q1, which represents a 10.4% growth rate, suggesting that the company's specialized medical and industrial component offerings maintain resilience despite broader macroeconomic volatility in the hardware sector.
The revenue growth appears to be supported by the company's deep integration into long-cycle medical OEM platforms, which provides a buffer against the cyclical softening observed in industrial laser markets. Investors should monitor whether this growth remains sustainable as post-pandemic supply chain normalization potentially reduces the backlog-driven revenue tailwinds seen in previous periods.
As reported in the financial statements, Novanta's gross margin fluctuated from a high of 44.8% in 2025Q3 to 41.8% in 2026Q1, indicating that the company's premium product mix is currently facing pressure from rising input costs or shifts in the underlying segment revenue composition.
The contraction in gross margin suggests that the company's high-fixed-cost manufacturing model is sensitive to utilization rates and specialized component pricing. While the 41.59% average remains competitive, the recent downward trend implies that maintaining pricing power in the face of industrial cyclicality may become increasingly challenging for management.
Based on the income statement figures, operating income scaled to $30.1 million in 2026Q1, yet the operating margin of 11.7% suggests that significant SG&A and R&D expenditures continue to absorb a substantial portion of gross profit, limiting the company's ability to demonstrate meaningful operating leverage.
The persistent investment in R&D is necessary to maintain the company's competitive moat in precision motion and optics, but it creates a high break-even point. Investors should evaluate whether the current level of administrative spending is a structural necessity for integration or if it represents an area where future efficiency gains could be realized.
Analysis of the reported figures reveals that net income volatility, ranging from $4.5 million in 2025Q2 to $21.1 million in 2026Q1, is heavily influenced by non-operating items, including acquisition-related compensation and stock-based compensation charges that frequently distort the underlying profitability of the core business operations.
The disparity between operating income and net income suggests that the company's aggressive M&A strategy introduces significant accounting noise through intangible asset amortization. Analysts should focus on adjusted earnings metrics to better understand the true cash-generating capability of the business, as GAAP figures may understate the operational performance.
While Novanta maintains a strong balance sheet, the income statement data indicates that the company's growth is heavily reliant on inorganic expansion, which may mask underlying organic stagnation and expose the firm to integration fatigue or the risk of overpaying for assets in a crowded medical technology market.
Short-term margin compression and the lumpy nature of revenue recognition for large OEM orders could lead to periods of earnings disappointment. If the company fails to successfully integrate its recent acquisitions, the high fixed-cost structure may exacerbate the impact of any downturn in the medical robotics or industrial automation sectors.
Quick answers to the most common questions about buying NOVTU stock.
For fiscal year 2025, Novanta Inc. Tangible Equity Units (NOVTU) reported total revenue of $980.6M. This represents a 0.0% increase compared to $980.6M in 2025.
Novanta Inc. Tangible Equity Units (NOVTU) is profitable, generating $53.8M in net income for the fiscal year ending 2025 with a net profit margin of 5.5%.
Novanta Inc. Tangible Equity Units (NOVTU) reported an operating income of $116.7M, resulting in an operating profit margin of 11.9%. This margin reflects the operational efficiency of the business before interest and taxes.
Novanta Inc. Tangible Equity Units (NOVTU) generated $407.8M in gross profit for the year, representing a gross profit margin of 41.6%. This demonstrates the company's core pricing power and production efficiency.